Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. - Wikidata - wikimedia - TriplyDB

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

http://www.wikidata.org/entity/Q30482634

about

Role and expression of FRS2 and FRS3 in prostate cancer Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Polyunsaturated fatty acid metabolism in prostate cancer Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer Novel therapies for metastatic castrate-resistant prostate cancer.Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.Pre-clinical mouse models of human prostate cancer and their utility in drug discovery Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer.A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study Overexpression of FGF9 in prostate epithelial cells augments reactive stroma formation and promotes prostate cancer progression.Ligand-targeted theranostic nanomedicines against cancer Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.Fibroblast growth factors, old kids on the new block.Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody.Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3.The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer.Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer.

P2860

Q21261288-5B8C6FCD-4CB5-44E8-8E12-29384C7DDFBD Q24302687-6F52F603-B33E-4049-801A-55A1C7DAF26D Q24629893-7A5FD12E-6072-4F1D-9FAD-7A144F7665C4 Q26797063-CAFC0809-12E5-45F1-8003-1B9E2E246AC4 Q27024775-607052B0-680A-46D3-B7DD-32A3AEAA04BB Q28247245-E1CB1BEA-082E-48E4-93F4-04CB4286009D Q30435146-C9A6C6A1-6C71-4CBF-A734-BD698BF218B8 Q33894635-BAC8BF56-3811-4D71-8752-6A68498B4745 Q34067118-523652FC-B5AE-4720-B802-6E8AEB0408C1 Q34168636-65E4196B-571D-460A-831B-5D78B4A12FFE Q34249263-5F94DDEB-7121-48EF-AE97-229B8DD60BCE Q34300613-75A52B10-7D40-4F76-846A-F5D1ACE352FD Q34549787-C4B0287A-24AD-43DB-8259-69C9E43ADF9F Q34699785-C1438236-9AE9-4390-8332-BA382284B177 Q34714945-56AEB50B-263F-4C02-A7AA-27E9F7C42135 Q34771567-23CF6CD3-472D-457A-82D6-B1292543F5D2 Q34809729-3F973C6B-8818-4FA6-A4D3-AD1ED1F479FF Q34981594-EB7C3342-ECEE-4B29-9CF1-0F92CED075DD Q34999463-974622BC-00D7-41FD-B439-A85EE66F57A5 Q35048908-F48D1E3B-FC66-4F08-8617-0D19D160C4F4 Q35148340-C323FE89-AE11-4204-A353-A00782BB81C5 Q35229487-F3F3EBB6-DC5C-4E72-8E40-E3E074553F13 Q35592471-DC376241-292A-4B96-849F-B17FCEF68B12 Q35830052-01B2167B-5A55-4F5C-9352-72A159F0F6A0 Q35895637-878199D7-BEAF-4767-B636-13A7C000B6CB Q36303927-3AE3A605-C01B-43E2-B1D4-0D399B6A579E Q36385066-C5967B31-C88A-4A73-9D40-9BF7A93AE4AC Q36436763-0F617B28-D653-432C-952A-16463AD7C071 Q36468744-FC1FD7C7-3139-43CF-84EF-483D119E6758 Q36660546-686CB5B7-2D55-4401-AA9F-0EA656E1434C Q36751712-36105BFA-6AD4-4D97-80F3-8830AE6A3FE8 Q36862668-0E3795C5-CBA1-4816-91C0-649D3180D484 Q36923642-CFB2541B-579F-4CBE-8BCC-6EAC5CD50525 Q36967528-FFA51E37-3452-41E4-A8A2-2E15E84C41A9 Q37185267-7E054979-225E-4D2C-B6FE-D47A91FC150D Q37392801-E2EC6DCA-FFDD-43BD-9606-E228702AFE30 Q37417870-24168491-91D8-4715-8B18-6895D220E5F0 Q37444366-14179769-F0D0-40B8-A1E0-E2B800B3C7FB Q37701569-99E229EA-5B96-4FA8-9F95-C197E046A0AF Q37732437-B27E895C-24F7-49A8-A5BD-534212B4A9FF

P2860

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

http://www.wikidata.org/entity/Q30482634

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Androgen receptor-negative hum ...... ough FGF9-mediated mechanisms.

@ast

Androgen receptor-negative hum ...... ough FGF9-mediated mechanisms.

@en

type

label

Androgen receptor-negative hum ...... ough FGF9-mediated mechanisms.

@ast

Androgen receptor-negative hum ...... ough FGF9-mediated mechanisms.

@en

prefLabel

Androgen receptor-negative hum ...... ough FGF9-mediated mechanisms.

@ast

Androgen receptor-negative hum ...... ough FGF9-mediated mechanisms.

@en

P1433

Q30482634-16D84A2C-946E-489B-8B4F-E7C86F1AEF54

P1476

Q30482634-C55B2FEC-237B-4E78-925D-BF9F388F7F34

P2093

Q30482634-05FC2E68-C9A4-4ECB-8C53-64D760DCC982

Q30482634-14E406FC-CFA4-434F-B7F6-23B99DC92683

Q30482634-15E15EDF-95E6-4A26-8331-F7FEE2E60CE7

Q30482634-1AEAD380-5F0B-4133-B395-B9F86418C73F

Q30482634-1F28C05C-96CD-4884-8626-040961E59189

Q30482634-25A1F6CE-91DA-4394-A26B-117CC6437EF8

Q30482634-262C1322-CF57-4FFC-BA13-3E5796A4652E

Q30482634-2ACB63A1-EE60-49ED-BFFF-9785B05EAEE5

Q30482634-36690F95-C8DA-420F-A128-68C6C8E21063

Q30482634-400B6522-1AE7-4D7A-A4A4-BBBB566F0CF5

P2860

Q30482634-0ED556EC-D67A-41FD-9AF5-033B568ACA16

Q30482634-1589BF92-C560-437B-AFFF-80E07F5D585B

Q30482634-1E313621-41C4-43AA-A40C-2268B281CCD6

Q30482634-211D3134-48B0-44ED-B33C-0965A39AA5B6

Q30482634-24CDBF54-6B03-407C-958C-9F8768FE631E

Q30482634-2F1A002D-C0DF-4A3C-8136-915FB64E514D

Q30482634-3BB10FD3-C60C-4D91-8085-AAD6190902C0

Q30482634-43A4C59F-349F-4A39-9A46-A020C591DD29

Q30482634-4644FCFD-1BAE-4E35-BCE3-CF6FBAAA5A95

Q30482634-498B96E4-169F-45F1-80BB-6DAB582B225E

P304

Q30482634-A7D1AAD3-6334-43C5-B0D8-1BC2C920EC19

P31

Q30482634-5E2EF7BC-67AB-4ED5-A801-B5E1EEF06F08

P356

Q30482634-417C3309-74A1-4D3E-801C-A6CD737627A2

P407

Q30482634-CB32CB70-67BE-4B1C-93D0-649803CB53E9

P433

Q30482634-1478DA1A-8CED-471A-9F2E-5FDE5EE12310

P478

Q30482634-2A823FDB-6486-4A75-98B6-DF47328D3901

P577

Q30482634-0657536D-A443-4682-80A7-8D18CFF8A613

P698

Q30482634-647DB791-EB2F-4D0B-B993-3CF1E35F233F

P932

Q30482634-E198AD57-E9BE-4A6C-B932-88408D5F398F

P356

P1433

Journal of Clinical Investigation

P1476

Androgen receptor-negative hum ...... ough FGF9-mediated mechanisms.

@en

P2093

Adriana Lopez

http://www.w3.org/2001/XMLSchema#string

Amado J Zurita

http://www.w3.org/2001/XMLSchema#string

Asha S Multani

http://www.w3.org/2001/XMLSchema#string

Austin K Raymond

http://www.w3.org/2001/XMLSchema#string

Charles Sikes

http://www.w3.org/2001/XMLSchema#string

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Elba S Vazquez

http://www.w3.org/2001/XMLSchema#string

Eleni Efstathiou

http://www.w3.org/2001/XMLSchema#string

Jie Liu

http://www.w3.org/2001/XMLSchema#string

Jing Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling

Fibroblast growth factors

Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection

FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Molecular determinants of resistance to antiandrogen therapy

Effects of FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential

Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

Bone morphogenetic proteins

P304

2697-2710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI33093

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18618013

http://www.w3.org/2001/XMLSchema#string

P932

2447924

http://www.w3.org/2001/XMLSchema#string